Study of renal safety in amphotericin B lipid complex-treated patients
Study of renal safety in amphotericin B lipid complex-treated patients
复制标题
DOI：
10.1086/429335
复制
发表时间：
2005-05-01
影响因子：
11.8
通讯作者：
Wingard, JR
中科院分区：
文献类型：
--
作者：
Alexander, BD;Wingard, JR
为了研究阿替霉素B脂质复合物（ABLC）的肾脏安全性，回顾了3514例接受ABLC治疗的真菌感染患者的记录。预测肌酐清除率（C（Cr））从基线至治疗结束的中位变化为-3 mL/ min（范围：-119至118 mL/ min）; 13%的患者发生血清肌酐（S-Cr）水平加倍，3%的患者需要进行新的透析。既往接受过抗真菌治疗的基础肾脏疾病患者的中位C-Cr为0.5 mL/ min（范围：-107至52 mL/ min）。尽管异基因造血干细胞移植受者肾损害的风险增加，但只有17%的患者显示治疗结束时S-Cr水平加倍，C-Cr的中位变化为-10 mL/ min（范围：-107至108 mL/ min）。在ABLC治疗的患者中，伴随使用潜在肾毒性药物治疗和基线S-Cr水平为
To investigate the renal safety of amphotericin B lipid complex ( ABLC), records from 3514 ABLC- treated patients with fungal infections were reviewed. The median change in predicted creatinine clearance ( C (Cr)) from baseline to the end of therapy was - 3 mL/ min ( range, - 119 to 118 mL/ min); doubling of serum creatinine ( S- Cr) level occurred in 13% of patients, and new dialysis was needed for 3% of patients. Patients with underlying renal disease who had received prior antifungal therapy demonstrated a median C-Cr of 0.5 mL/ min ( range, - 107 to 52 mL/ min). Despite increased risk for renal impairment in allogeneic hematopoietic stem- cell transplant recipients, only 17% of patients demonstrated end- of- therapy doubling of S- Cr levels, and the median change in C-Cr was - 10 mL/ min ( range, -107 to 108 mL/ min). In ABLC- treated patients, concomitant treatment with potentially nephrotoxic agents and a baseline S- Cr level of